Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Tarsus Pharmaceuticals, Inc. | d30607ds1.htm |
| EX-10.14 - EX-10.14 - Tarsus Pharmaceuticals, Inc. | d30607dex1014.htm |
| EX-10.13 - EX-10.13 - Tarsus Pharmaceuticals, Inc. | d30607dex1013.htm |
| EX-10.9 - EX-10.9 - Tarsus Pharmaceuticals, Inc. | d30607dex109.htm |
| EX-10.8 - EX-10.8 - Tarsus Pharmaceuticals, Inc. | d30607dex108.htm |
| EX-10.7 - EX-10.7 - Tarsus Pharmaceuticals, Inc. | d30607dex107.htm |
| EX-10.6 - EX-10.6 - Tarsus Pharmaceuticals, Inc. | d30607dex106.htm |
| EX-10.2 - EX-10.2 - Tarsus Pharmaceuticals, Inc. | d30607dex102.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated August 7, 2020, in the Registration Statement (Form S-1) and related Prospectus of Tarsus Pharmaceuticals, Inc. dated September 25, 2020.
| /s/ Ernst & Young LLP |
Irvine, California
September 25, 2020